Answers are grounded in this paper and cite their sources.
Purpose of review Randomized clinical trials increasingly guide rhinology as clinicians weigh biologics, topical drug-delivery systems, surgery, and structural interventions. This invited review highlights five randomized clinical trials or trial programs that have meaningfully influenced contemporary rhinology practice. Recent findings The selected trials address common decision points across chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), and nasal airway obstruction. LIBERTY NP SINUS-24 and SINUS-52 established dupilumab as a benchmark biologic therapy for severe CRSwNP. WAYPOINT supports thymic stromal lymphopoietin inhibition as an effective upstream biologic strategy in severe CRSwNPReOpen1 and ReOpen2 showed that exhalation delivery of fluticasone improves symptoms and radiographic sinus opacification in CRS, including patients without polyps. A pragmatic randomized trial supported endoscopic sinus surgery plus medical therapy as more effective than medical therapy alone in CRSwNP. NAIROS demonstrated superior patient-reported outcomes after septoplasty compared with standardized medical management in adults with nasal obstruction associated with septal deviation. Summary Together, these trials move rhinology toward more evidence-based, mechanism-informed, and patient-centered treatment selection while highlighting the need for comparative-effectiveness studies and predictive biomarkers.
No takes yet. Share an insight, caveat, or question.
Bui-Nguyen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: